Growth Hormone (Somatropin) vs hCG (Human Chorionic Gonadotropin)

Mechanism

Recombinant human growth hormone (rhGH/somatropin) is a 191-amino acid protein identical to endogenous GH. It binds the GH receptor (GHR), a type I cytokine receptor, activating the JAK2-STAT5 signaling cascade that drives hepatic IGF-1 production — the primary mediator of GH's anabolic effects. GH directly stimulates lipolysis via hormone-sensitive lipase (HSL) activation and inhibits lipogenesis. It promotes chondrocyte proliferation, collagen synthesis, and linear bone growth. GH also enhances protein synthesis through mTOR pathway activation and improves nitrogen balance. Pulsatile secretion patterns are important — continuous GH exposure preferentially drives IGF-1, while pulsatile release favors direct lipolytic effects.

Standard Dosing

Research indicates 1-2 IU/day (0.33-0.67 mg/day) subcutaneously for anti-aging and body composition. Clinical GHD replacement: 0.2-0.6 mg/day titrated to IGF-1 levels.

Timing

Inject subcutaneously in the morning fasted (mimics physiological pulse) or before bed (mimics nocturnal secretion). Rotate injection sites (abdomen, thigh, deltoid). If using with insulin, separate GH injection by several hours. Fasted-state injection preferred for maximal lipolytic effect.

Cycle Duration

Long-term (6-12+ months) for body composition benefits. Clinical GHD replacement is indefinite. Minimum 3-6 months to assess efficacy.

Side Effects

• Fluid retention and edema (dose-dependent, typically resolves in 2-4 weeks)
• Carpal tunnel syndrome and joint pain
• Insulin resistance and elevated fasting glucose
• Headache
• Numbness and paresthesias
• Potential increased cancer risk with chronic supraphysiological IGF-1 levels
• Gynecomastia
• Acromegalic features with long-term excessive dosing (jaw growth, digit enlargement)

Contraindications

• Active malignancy (GH/IGF-1 promotes cell proliferation)
• Active proliferative or preproliferative diabetic retinopathy
• Acute critical illness (GH increased mortality in ICU patients)
• Active intracranial lesion or tumor
• Prader-Willi syndrome with severe obesity or respiratory impairment
• Closed epiphyses (for linear growth indication only)

Best Stacking Partners

Mechanism

hCG mimics luteinizing hormone (LH) by binding the LH/CG receptor on testicular Leydig cells, activating the cAMP-PKA signaling cascade that upregulates steroidogenic acute regulatory protein (StAR) and CYP11A1, driving cholesterol conversion to pregnenolone and downstream testosterone synthesis. By maintaining intratesticular testosterone (ITT) levels during exogenous testosterone administration, hCG preserves Leydig cell function, spermatogenesis, testicular volume, and the production of neurosteroids (pregnenolone, DHEA) and estradiol within the testes.

Standard Dosing

Research indicates 250-500 IU administered subcutaneously 2-3 times per week as a TRT adjunct for fertility and testicular maintenance.

Timing

Administer on non-testosterone injection days if using twice-weekly TRT split. Consistent schedule (e.g., Tuesday/Saturday). Refrigerate reconstituted solution; use within 30-60 days.

Cycle Duration

Ongoing for as long as TRT continues and fertility preservation is desired. Can be used in 4-8 week pre-PCT bursts to 'prime' testicular recovery.

Side Effects

• Elevated estradiol (from intratesticular aromatization)
• Injection site reactions
• Headache
• Gynecomastia (if E2 rises unchecked)
• Mood swings
• Potential Leydig cell desensitization at excessive doses (>1500 IU per dose)

Contraindications

• Androgen-dependent neoplasia (prostate cancer)
• Precocious puberty
• hCG-secreting tumors
• Known hypersensitivity to hCG

Best Stacking Partners